Asset Team Lead Palenziq and PKU

BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions. Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions. Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world. About Commercial Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies BioMarin’s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.

Asset Team Lead (ATL) Palynziq and PKU   Overview Description   Serves as the single point of accountability for end-to-end asset success. Primary liaison with executive management and the ET Business Unit on the asset strategy and has overall accountability to executive management for the integrated asset strategy. Acts as the asset champion and leads the cross-functional team of functional leaders that together develop and execute the integrated asset strategy. Expected to drive decision-making forward, facilitate cross-functional collaboration, and ensure that the asset strategy aligns with BioMarin’s enterprise goals.     Commits to developing and facilitating the strategic conversations that advance the asset—both within the Asset Team and across the organization. Leads with urgency towards the attainment of key milestones and adherence to the path that optimally balances risk and value creation. Commits to establishing a culture of inclusivity and collaboration—and to proactively facilitating and integrating the cross-functional dialogue needed to develop the integrated asset strategy and compelling recommendations that will enable confident executive-level decision-making. Does so in a way that is optimal and objective, critically analyzing strengths, weaknesses, opportunities, and threats.

Strategic Planning     •         Ensures the integrated asset strategy is closely connected to ET Business Unit priorities, commercial objectives, and portfolio trade-offs.   •         Leads the development and execution of the integrated asset strategy, ensuring alignment with BioMarin’s enterprise objectives, to maximize an asset’s potential for patients and value proposition for BioMarin   •         Shapes the strategy across the asset lifecycle, from development to commercialization & the lifecycle post initial launch (e.g., next-generation products)   •         Drives critical decision-making by proactively communicating strategic challenges and opportunities as new relevant information emerges   •         Ensures integrated stage gate plans are aligned with the integrated asset strategy and ensures assumptions and drivers are aligned with plans to inform financial planning   •         Sets aspirational goals for timelines and budget   •         Partners with functional leaders to ensure appropriate resource allocation to accomplish goals   •